Skip to main content
. 2022 Mar 24;27(7):536–e553. doi: 10.1093/oncolo/oyab080
Number of patients screened 10
Number of patients enrolled 10
Number of patients evaluable for toxicity 10
Number of patients evaluated for efficacy 10
Evaluation method RECIST 1.1
Response assessment CR n = 0 (0%)
Response assessment PR n = 0 (0%)
Response assessment SD n = 4 (40%)
Response assessment PD n = 6 (60%)
Median duration of treatment 2.9 months